- Home
- DYAI vs ENLV Comparison
DYAI vs ENLV Comparison
Compare DYAI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- ENLV
- Stock Information
- Founded
- DYAI 1979
- ENLV 2005
- Country
- DYAI United States
- ENLV Israel
- Employees
- DYAI N/A
- ENLV N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- ENLV Health Care
- Exchange
- DYAI Nasdaq
- ENLV Nasdaq
- Market Cap
- DYAI 30.2M
- ENLV 26.6M
- IPO Year
- DYAI 2004
- ENLV 1995
- Fundamental
- Price
- DYAI $0.92
- ENLV $0.98
- Analyst Decision
- DYAI Strong Buy
- ENLV Strong Buy
- Analyst Count
- DYAI 1
- ENLV 2
- Target Price
- DYAI $3.00
- ENLV $10.00
- AVG Volume (30 Days)
- DYAI 100.8K
- ENLV 128.7K
- Earning Date
- DYAI 11-12-2025
- ENLV 11-28-2025
- Dividend Yield
- DYAI N/A
- ENLV N/A
- EPS Growth
- DYAI N/A
- ENLV N/A
- EPS
- DYAI N/A
- ENLV N/A
- Revenue
- DYAI $3,342,195.00
- ENLV N/A
- Revenue This Year
- DYAI $18.18
- ENLV N/A
- Revenue Next Year
- DYAI $87.65
- ENLV N/A
- P/E Ratio
- DYAI N/A
- ENLV N/A
- Revenue Growth
- DYAI N/A
- ENLV N/A
- 52 Week Low
- DYAI $0.71
- ENLV $0.81
- 52 Week High
- DYAI $2.20
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- DYAI 36.54
- ENLV 38.07
- Support Level
- DYAI $0.88
- ENLV $1.03
- Resistance Level
- DYAI $0.98
- ENLV $1.05
- Average True Range (ATR)
- DYAI 0.08
- ENLV 0.04
- MACD
- DYAI -0.02
- ENLV -0.00
- Stochastic Oscillator
- DYAI 11.93
- ENLV 8.95
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.